Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery (Q36670473)

15 August 2017

1 reference

title

Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery (English)

1 reference

15 August 2017

1 reference

1 reference

Matthew M Cooney

1

1 reference

15 August 2017

Willem van Heeckeren

2

1 reference

15 August 2017

Shyam Bhakta

3

1 reference

15 August 2017

Jose Ortiz

4

1 reference

15 August 2017

Scot C Remick

5

1 reference

15 August 2017

publication date

1 December 2006

1 reference

Nature Clinical Practice Oncology

15 August 2017

published in

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

682-692

1 reference

Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

In vivo targets of recombinant human tumour necrosis factor-alpha: blood flow, oxygen consumption and growth of isotransplanted rat tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

An appraisal of transcatheter arterial embolization combined with transcatheter arterial infusion of chemotherapeutic agent for hepatic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Hepatic arterial chemotherapy and occlusion for palliation of primary hepatocellular and unknown primary neoplasms in the liver

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Angiogenic attack as a therapeutic strategy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Vascular targeting as a strategy for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Targeting tumour vasculature: the development of combretastatin A4.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Molecular regulation of vessel maturation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Tumour vascular targeting

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Blood vessel maturation: vascular development comes of age

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Flavone acetic acid--preclinical and clinical activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouse

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Vinca alkaloids: anti-vascular effects in a murine tumour

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Blood flow failure as a major determinant in the antitumor action of flavone acetic acid.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Transplacental carcinogenesis by stilbestrol

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Tumor angiogenesis: past, present and the near future

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Overview of angiogenesis: Biologic implications for antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Phase I trial of combretastatin a-4 phosphate with carboplatin

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0663

7 January 2021

Identifiers

DOI

10.1038/NCPONC0663

1 reference

15 August 2017

1 reference